Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis

  • Koji Takahashi
    Department of Community Emergency Medicine, Ehime University Graduate School of Medicine, Ehime, Japan
  • Yoshiyasu Hiratsuka
    Department of Radiology, Yawatahama City General Hospital, Ehime, Japan
  • Takaaki Iwamura
    Department of Radiology, Yawatahama City General Hospital, Ehime, Japan
  • Daisuke Sasaki
    Department of Radiology, Yawatahama City General Hospital, Ehime, Japan
  • Nobuhisa Yamamura
    Department of Clinical Pathology, Yawatahama City General Hospital, Ehime, Japan
  • Sohei Kitazawa
    Department of Molecular Pathology, Ehime University Graduate School of Medicine, Ehime, Japan
  • Mitsuharu Ueda
    Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
  • Hiroe Morioka
    Department of Cardiology, Yawatahama City General Hospital, Ehime, Japan
  • Takafumi Okura
    Department of Cardiology, Yawatahama City General Hospital, Ehime, Japan
  • Daijiro Enomoto
    Department of Cardiology, Yawatahama City General Hospital, Ehime, Japan
  • Shigeki Uemura
    Department of Cardiology, Yawatahama City General Hospital, Ehime, Japan
  • Taizo Kono
    Department of Radiology, Yawatahama City General Hospital, Ehime, Japan
  • Tomoki Sakaue
    Department of Community Emergency Medicine, Ehime University Graduate School of Medicine, Ehime, Japan
  • Shuntaro Ikeda
    Department of Community Emergency Medicine, Ehime University Graduate School of Medicine, Ehime, Japan

この論文をさがす

説明

Technetium-99m-pyrophosphate (99mTc-PYP) uptake in the internal oblique muscle (IOM), which is often observed in patients with wild-type transthyretin cardiac amyloidosis (ATTR-CA), indicates amyloid transthyretin (ATTR) deposition. This study aimed to assess the safety and efficacy of 99mTc-PYP imaging-based computed tomography (CT)-guided core-needle biopsy of the IOM as a new extracardiac screening biopsy for confirming the presence of ATTR deposits. Patients with suspected ATTR-CA in whom myocardial tracer uptake was detected on chest- and abdomen-centered images of 99mTc-PYP scintigraphy underwent CT-guided core-needle biopsy at the site with the highest tracer uptake in the IOM between September 2021 and November 2022. All 18 consecutive patients (mean age, 86.3 years ± 6.5; 61.1% male) enrolled in the study showed 99mTc-PYP uptake into the IOM. Adequate tissue samples were obtained from all patients except one without serious complications. Immunohistochemical analysis confirmed ATTR deposits in 16/18 (88.9%) patients. In the remaining two patients, ATTR deposits were observed via endomyocardial biopsy. All patients were diagnosed with wild-type ATTR-CA based on transthyretin gene sequence testing results. In wild-type ATTR-CA, 99mTc-PYP imaging-based CT-guided core-needle biopsy of the IOM could be used as an extracardiac screening biopsy to confirm the presence of ATTR deposits.

収録刊行物

  • Amyloid

    Amyloid 31 (1), 12-21, 2023-07-24

    Informa UK Limited

被引用文献 (2)*注記

もっと見る

参考文献 (37)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ